Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant herpes simplex virus type 1 vaccine (Beijing Luzhu Biotechnology)
- Development stage
- Preclinical
- Lead developer
- Beijing Luzhu Biotechnology
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Beijing Luzhu Biotechnology's recombinant herpes simplex virus type 1 (HSV-1) vaccine is a protein subunit candidate currently in preclinical development. It is designed to prevent or treat oral herpes (herpes labialis) by eliciting a targeted immune response against HSV-1 antigens. The vaccine utilizes recombinant protein technology, a platform the company also employs for its more advanced shingles vaccine (LZ901). By focusing on specific viral proteins, the vaccine aims to provide a safer and more effective alternative to traditional live-attenuated or inactivated virus approaches for managing HSV-1 infections. It is part of a broader pipeline at Luzhu Biotechnology that includes vaccines for both HSV-1 and HSV-2.
- Other names
- HSV-1 recombinant protein vaccineHSV1 recombinant protein vaccineHSV 1 recombinant protein vaccineBeijing Luzhu HSV-1 vaccinerecombinant HSV-1 vaccine
Beyond the preview
Go deeper on recombinant herpes simplex virus type 1 vaccine (Beijing Luzhu Biotechnology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant herpes simplex virus type 1 vaccine (Beijing Luzhu Biotechnology).